Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Dizal Pharmaceuticals: Clinical Trials & FDA Approval Profile

Dizal Pharmaceuticals (Global / Institutional) sponsors 23 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 15 active protocols (11 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.3%
Median Closed Enrollment vs National (145 pts)58 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Dizal Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)23
Active Pipeline (Recruiting Now)15 (11)
Completed vs Stopped Early7 / 1 (4.3%)
Median Closed Actual Enrollment58 participants
Physical Hospital Site Disclosure93.8% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Dizal Pharmaceuticals
Hospital Research SiteLocationShared Protocols
Hunan Cancer HospitalChangsha, Hunan10
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei9
Henan Cancer HospitalZhengzhou, Henan9

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Dizal Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07154264A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)Phase IIRECRUITING
NCT07234162A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)Phase IIIRECRUITING
NCT05712902Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Phase IIACTIVE NOT RECRUITING
NCT06511869AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)Phase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Dizal Pharmaceuticals Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI